Home > Boards > US Listed > Biotechs > Pacific Biosciences of California, Inc. (PACB)

Simon-Barnett By Simon Barnett / @sbarnettARK

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
G3trich Member Profile
 
Followed By 33
Posts 649
Boards Moderated 0
Alias Born 12/30/13
160x600 placeholder
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 9/20/2021 5:21:42 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 9/20/2021 5:02:09 PM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 9/20/2021 4:47:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/20/2021 4:08:14 PM
Pacific Biosciences Closes Acquisition of Omniome and Establishes San Diego Presence GlobeNewswire Inc. - 9/20/2021 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/17/2021 4:54:33 PM
Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conferences GlobeNewswire Inc. - 9/3/2021 9:00:00 AM
Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conference GlobeNewswire Inc. - 8/9/2021 8:00:00 AM
Softbank builds $5B stake in Roche - Bloomberg Seeking Alpha - 8/4/2021 1:01:14 PM
Pacific Biosciences Snaps up Circulomics; Shares Fall 3.3% TipRanks - 8/4/2021 2:31:34 AM
Pacific Biosciences posts revenue beat even as net loss widens amid rising SG&A expenses Seeking Alpha - 8/3/2021 5:21:34 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/3/2021 4:13:45 PM
Pacific Biosciences of California, Inc. Announces Second Quarter 2021 Financial Results GlobeNewswire Inc. - 8/3/2021 4:05:00 PM
Pacific Biosciences acquires DNA extraction company Circulomics Seeking Alpha - 8/3/2021 8:25:38 AM
Pacific Biosciences Acquires Circulomics – A Leading High Molecular Weight DNA Extraction Company GlobeNewswire Inc. - 8/3/2021 8:00:00 AM
Pacific Biosciences Grants Equity Incentive Award to New Employee GlobeNewswire Inc. - 7/28/2021 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/20/2021 7:31:42 AM
Pacific Biosciences and Invitae Announce Intent to Expand Collaboration GlobeNewswire Inc. - 7/20/2021 7:02:00 AM
Pacific Biosciences Signs Definitive Agreement to Acquire Omniome GlobeNewswire Inc. - 7/20/2021 7:00:00 AM
Pacific Biosciences of California, Inc. Second Quarter 2021 Financial Results Call GlobeNewswire Inc. - 7/19/2021 4:05:00 PM
PacBio collaborating with genomic medicine institute on genomic sequencing Seeking Alpha - 6/23/2021 4:31:36 PM
Pacific Biosciences and Rady Children’s Institute for Genomic Medicine Announce its First Research Collaboration for Whole... GlobeNewswire Inc. - 6/23/2021 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/17/2021 4:32:29 PM
Pacific Biosciences Grants Equity Incentive Award to New Employee GlobeNewswire Inc. - 6/11/2021 4:05:00 PM
Pacific Biosciences Welcomes Neil Ward to Its Leadership Team as Vice President and General Manager for Europe, Middle East,... GlobeNewswire Inc. - 6/8/2021 2:00:00 AM
G3trich   Tuesday, 01/19/21 04:51:21 PM
Re: None
Post # of 1048 
Simon-Barnett By Simon Barnett | @sbarnettARK
Analyst

During the J.P. Morgan Healthcare Conference last week, Invitae (NVTA), a leading medical genetics company, and Pacific Biosciences “PacBio” (PACB), a provider of long-read sequencing instruments, announced a collaboration to develop an ultra-high-throughput sequencing platform based on PacBio’s HiFi sequencing chemistry. This collaboration could increase the number of threats to companies focused on short-read sequencing.

Bolstered not only by results from this year’s PrecisionFDA Truth Challenge but also by improvements in HiFi accuracy via Google’s (GOOGL) DeepVariant as well as research community feedback, we think PacBio’s HiFi sequencing method provides the most complete and accurate view of the human genome.

To drive widespread adoption, PacBio likely needs to improve instrument throughput and variable cost. Collaborating with Invitae, we imagine PacBio can gain critical insights into its customers’ challenges, from automated sample prep to large-scale data processing. Invitae’s high sample volume could help PacBio’s long-read sequencing to capitalize on its Wright’s Law curve, as costs decline 28% for every cumulative doubling in the number of whole human genomes sequenced on long-read machines.

In our opinion, HiFi sequencing should help Invitae pull further away from its competition in the molecular diagnostics space, enabling the detection and evaluation of hard-to-sequence variants that could change patient management meaningfully. Unlike with short-read sequencing, HiFi-sequenced genomes should allow for the digital reassessment of patients’ DNA throughout their lifetimes, especially as researchers learn more about hard-to-sequence genes and the effects of structural variation within the human genome.

Ultimately, we believe the combination of talent, resources, know-how, and sample volume should allow both companies push long-read sequencing into routine medical practice faster than otherwise would be the case. By publishing data on clinical utility and diagnostic yields across disease types, they also should be able to demonstrate the system-wide value of HiFi sequencing over short-read whole genome sequencing.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences